OviTex Reinforced Tissue Matrix
DeviceAll study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
NCT Number: NCT07070115
This study will evaluate hiatal hernia recurrence rate and post-operative complications following the use of OviTex Core Resorbable or OviTex 1S Resorbable.
Interested in participating?
Request Info22 year and older
All sexes
Interventional
Not applicable
University of South Alabama Health, Mobile, Alabama, United States
This prospective, open-label, multicenter, non-randomized, post-market study will enroll up to 173 subjects in the United States. Patients undergoing an elective hiatal hernia repair and who meet all eligibility criteria will be enrolled in the study. Subjects will undergo minimally invasive procedures for hiatal hernia repair with the use of OviTex Core Resorbable or OviTex 1S Resorbable for reinforcement. Subjects will have clinical follow-up through 5 years. Data collected in this study will be compared to a literature control at 24 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
(Baseline):
Exclusion criteria
(Intra-operative):
All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
Time frame: At 24 months
Incidence of radiographic recurrence at 24 months, defined as > 2cm above the hiatus via barium swallow.
Time frame: Occurring within the first 3 months of the hiatal hernia repair
Incidence of early post-operative device-related complications noted at the hernia repair site occurring ≤ 90 days after index hiatal hernia repair
Contact information is provided by the study sponsor or research team.
Danielle Campbell
CONTACT
Melissa LaMantia, MA
CONTACT
Tela Bio Inc
Industry
A Prospective Study Evaluating Clinical Hiatal Hernia Outcomes Using OviTex® Reinforced Tissue Matrix
Acronym: ECH2O2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07267494
Diastasis Recti, Hernia
Sacramento, California, United States
View Trial DetailsNCT00260585
Deglutition Disorders, Digestive System Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06444347
Hernia, Hernia, Diaphragmatic
Los Angeles, California, United States
View Trial DetailsNCT06725433
Disease Attributes, Hernia
Kuopio, Finland
View Trial Details